阿立哌唑合并帕罗西汀治疗抑郁症对照研究

Aripiprazole merger paroxetine for the treatment of depression contrast analysis

目的探讨阿立哌唑合并帕罗西汀治疗抑郁症的疗效和安全性。方法将符合入组标准和排除标准的无精神病性症状的抑郁症患者68例，随机分成2组，分别给于阿立哌唑合并帕罗西汀（合并组）和单用帕罗西汀（对照组），治疗12周，以汉密尔顿抑郁量表（HAMD）和汉密尔顿焦虑量表（HAMA）评定临床疗效，以治疗中出现的症状量表（TESS）和相关检查评定不良反应。并在治疗开始后第4，8周末各进行一次血常规，尿常规及血生化，心电图检查。结果合用组在治疗起效与症状改善时间上均较单用纽效果好。结论阿立哌唑合并帕罗西汀治疗无精神病性症状的抑郁症起效快．疗效优于单用帕罗西汀。不良反应无明显的增多或加章。

Objective To explore the aripiprazole merger paroxetine therapy efficacy and safety of the depression. Methods To conform to the standards and exclusion standard of psychiatric symptoms of depression,68 randomly divided into two groups to aripiprazole merger paroxetine （merger） and single paroxetine （control group）, treatment, 12 weeks Hamilton depression scale（HAMD） and Hamihon anxiety scale （HAMA）, to assess clinical curative effect in the treatment emergent symptoms scale （TESS） and the relevant examination evaluation of adverse reactions. And after the start of treatment in the first 4,8 weekend a routine blood, routine urine and blood biochemical and cardiogram. Results Share in treatment group works with symptoms improved both on time with good effect in groups. Conclusion Aripiprazole merger paroxetine treatment without mental symptoms of depression, rapid, effect of paroxetine. No obvious adverse reaction of increasing or worse.